|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.92 USD | +0.48% |
|
-0.25% | -2.13% |
| 08:52am | Rate Cuts Can't Buy Confidence |  |
| 07:06am | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
Company Valuation: Pfizer Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 204,605 | 331,440 | 287,626 | 162,560 | 150,345 | 146,691 | - | - |
| Change | - | 61.99% | -13.22% | -43.48% | -7.51% | -2.43% | - | - |
| Enterprise Value (EV) 1 | 232,220 | 338,807 | 300,723 | 221,758 | 194,219 | 187,334 | 184,486 | 180,206 |
| Change | - | 45.9% | -11.24% | -26.26% | -12.42% | -3.55% | -1.52% | -2.32% |
| P/E ratio | 21.5x | 15.3x | 9.37x | 77.8x | 18.8x | 13.4x | 11.3x | 11.5x |
| PBR | 3.24x | 4.3x | 3x | 1.83x | 1.7x | 1.62x | 1.58x | 1.56x |
| PEG | - | 0x | 0.2x | -0.8x | 0x | 0.4x | 0.6x | -5.85x |
| Capitalization / Revenue | 4.88x | 4.08x | 2.87x | 2.78x | 2.36x | 2.35x | 2.38x | 2.45x |
| EV / Revenue | 5.54x | 4.17x | 3x | 3.79x | 3.05x | 3x | 2.99x | 3.01x |
| EV / EBITDA | 13x | 13.3x | 7.1x | 14.2x | 6.74x | 7.55x | 7.3x | 7.49x |
| EV / EBIT | 17.8x | 16.7x | 8.07x | 23.8x | 8.91x | 8.7x | 8.49x | 8.7x |
| EV / FCF | 19.1x | 11.3x | 11.6x | 46.3x | 19.7x | 10.7x | 9.54x | 9.82x |
| FCF Yield | 5.23% | 8.82% | 8.66% | 2.16% | 5.06% | 9.34% | 10.5% | 10.2% |
| Dividend per Share 2 | 1.52 | 1.56 | 1.61 | 1.65 | 1.68 | 1.705 | 1.74 | 1.771 |
| Rate of return | 4.13% | 2.64% | 3.14% | 5.73% | 6.33% | 6.61% | 6.75% | 6.86% |
| EPS 2 | 1.71 | 3.85 | 5.47 | 0.37 | 1.41 | 1.932 | 2.28 | 2.235 |
| Distribution rate | 88.9% | 40.5% | 29.4% | 446% | 119% | 88.3% | 76.3% | 79.2% |
| Net sales 1 | 41,908 | 81,288 | 100,330 | 58,496 | 63,627 | 62,518 | 61,742 | 59,786 |
| EBITDA 1 | 17,801 | 25,426 | 42,336 | 15,590 | 28,801 | 24,813 | 25,280 | 24,046 |
| EBIT 1 | 13,024 | 20,235 | 37,272 | 9,300 | 21,788 | 21,538 | 21,735 | 20,708 |
| Net income 1 | 9,616 | 21,979 | 31,372 | 2,119 | 8,031 | 11,103 | 13,052 | 12,829 |
| Net Debt 1 | 27,615 | 7,367 | 13,097 | 59,198 | 43,874 | 40,642 | 37,795 | 33,515 |
| Reference price 2 | 36.81 | 59.05 | 51.24 | 28.79 | 26.53 | 25.80 | 25.80 | 25.80 |
| Nbr of stocks (in thousands) | 5,558,397 | 5,612,867 | 5,613,315 | 5,646,413 | 5,666,990 | 5,685,708 | - | - |
| Announcement Date | 2/2/21 | 2/8/22 | 1/31/23 | 1/30/24 | 2/4/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 13.36x | 2.99x | 7.54x | 6.61% | 147B | |
| 44.13x | 14.61x | 32.42x | 0.59% | 904B | |
| 20.04x | 5.62x | 15.56x | 2.46% | 506B | |
| 52.26x | 7.42x | 17.56x | 2.91% | 396B | |
| 18.45x | 4.63x | 11.61x | 3.11% | 342B | |
| 27.47x | 5.2x | 15.42x | 1.77% | 283B | |
| 18.42x | 4.97x | 11.71x | 3.06% | 256B | |
| 12.79x | 4.19x | 8.95x | 3.27% | 246B | |
| 13.86x | 4.96x | 10.26x | 3.64% | 223B | |
| 25.01x | 5.93x | 10.2x | 3.01% | 171B | |
| Average | 24.58x | 6.05x | 14.12x | 3.04% | 347.36B | |
| Weighted average by Cap. | 29.36x | 7.74x | 18.08x | 2.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- PFE Stock
- Valuation Pfizer Inc.
Select your edition
All financial news and data tailored to specific country editions
